SCHEMBL10003601

SCHEMBL10003601

CCc1nc2c(cc1Nc1ccc(OC)cc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.39
▸ AKR1C3 P42330 6/20 0.38
▸ AKR1C2 P52895 6/20 0.38
▸ ACP1 P24666 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ SLC2A1 P11166 1/20 0.36
▸ CTSV O60911 1/20 0.36
▸ CTSL P07711 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ GRIA2 P42262 1/20 0.35
▸ GRIA4 P48058 1/20 0.35
▸ TERT O14746 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PAX8 Q06710 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003245 0.91 MEN1 (0.38) LMNAIDO1TDO2MAPTMEN1
SCHEMBL10003693 0.91 CDC25B (0.41) ATMPOLBSLC2A1MAPTMEN1
SCHEMBL10003604 0.91 AKR1C3 (0.41) AKR1C3AKR1C2CNR2MEN1KMT2A
SCHEMBL10003518 0.90 RORC (0.38) AKR1C3AKR1C2POLBLMNAIDO1
SCHEMBL10003568 0.88 NPC1 (0.44) LMNAMAPTMEN1KMT2A
SCHEMBL10003992 0.86 CNR2 (0.39) AKR1C3AKR1C2CNR2MAPTMEN1
SCHEMBL10003500 0.84 PTPN11 (0.41) POLBMAPTGRIA2GRIA4
SCHEMBL10003818 0.84 MEN1 (0.38) AKR1C3AKR1C2CNR2LMNAMAPT
SCHEMBL10003155 0.83 P2RX7 (0.37) CNR2LMNAMAPTMEN1KMT2A
SCHEMBL10003070 0.82 SMO (0.49) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ATM 2136/4885AKR1C3 1934/4885AKR1C2 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback